Market Newsdesk

SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) — The AI revolution is well underway in the workplace, but a new survey from WalkMe, an SAP company and pioneer of the Digital Adoption Platform (DAP) category, reveals that employees are being left to navigate it on their own. The company’s second annual “AI in the Workplace Survey” finds that while workers are eager, most lack the support needed to use AI responsibly and effectively, fueling risk, wasted productivity, and lost ROI.

Shadow AI is everywhere

AI tools are flooding the workplace — but often without IT’s approval. 78% of employees say they use AI tools not provided by their employer, while more than half (51%) report conflicting guidance on when and how to use AI. This unmanaged use may create significant security and compliance risks.

The productivity paradox

Employees overwhelmingly believe in AI’s potential, with 80% saying it improves productivity. Yet nearly 60% admit it often takes longer to figure out how to use AI than to complete the task manually. Without proper guidance, AI’s promise is stalling, which at scale may mean thousands of lost hours and millions in wasted investment.

“Beyond the productivity paradox, we’re facing a full-blown governance crisis,” said Dan Adika, CEO and Co-founder, WalkMe. “When nearly 80% of employees are using shadow AI tools, organizations are not just losing money – they’re losing control. Businesses are missing a massive opportunity to strategically empower their people and realize the full potential of AI.”

AI stigma at work
Cultural confusion is compounding the problem. Nearly half (45%) of workers admit they have pretended to know how to use it in a meeting or presentation to avoid scrutiny. And yet 49% admit they have claimed not to use AI to avoid judgment. This trend is even more pronounced among Gen Z: 55.5% of Gen Z employees say they’ve pretended to understand AI tools, and 62% have hidden their use altogether.

Training gap blocks ROI

The enablement gap is stark. The number of daily AI users increased by 16 points since last year’s survey, but only 7.5% of employees have received extensive AI training. An additional 23% report receiving no training at all. This is a costly problem: WalkMe’s own 2025 State of Digital Adoption Report found that companies lost an average of $104 million in 2024 due to underused tools and poor rollout.

“AI has become an essential enterprise skill. But without training and guardrails, shadow AI creates risk and undermines ROI,” said Gina Smith, PhD, Research Director, IT Skills for Digital Business, IDC. “The companies that build AI‑ready skills and digital adoption strategies now can avoid such loss. They are the organizations who will lead the next era of work.”

Methodology
This report is based on a survey conducted by Propeller Insights on behalf of WalkMe between July 16 and 23, 2025. The survey polled 1,000 working U.S. adults who use AI in their jobs in some capacity. The sample was balanced to be nationally representative across age, gender, industry, company size, and seniority. The margin of error for the total sample is ±3 percentage points. The survey was designed to screen for employees who use AI at work, so the 100% adoption rate is by design and not a representation of the broader U.S. workforce.

About WalkMe:

WalkMe, an SAP company, pioneered the world’s leading Digital Adoption Platform, enabling organizations to navigate the change brought on by technology. Leveraging over a decade of experience, WalkMe’s platform integrates generative AI to deliver proactive, accessible, and actionable insights. Our context-aware solutions guide users through any workflow, identifying and resolving digital friction to ensure seamless execution of critical processes across all departments. Trusted by global leaders like IBM, Nestlé, ThermoFisher Scientific, and the U.S. Department of Defense, WalkMe empowers organizations to maximize software ROI and drive people-centric digital transformation. Visit www.walkme.com.

Media Contact:

Melanie Pasch
[email protected]

BOSTON HEIGHTS, Ohio, Aug. 27, 2025 (GLOBE NEWSWIRE) — Arhaus (NASDAQ: ARHS), a leader in artisan-crafted home furnishings, today introduced its annual style issue, ‘Home & Style’, and Fall 2025 Collection now available at Arhaus.com and in over 100 showrooms nationwide. This year’s style issue celebrates the season’s guiding theme—Home is a Feeling—woven throughout a collection inspired by the quiet comfort of belonging: laughter in the next room, a seat saved just for you, and the spaces that make a house a home.

“The expression of our new fall collection evokes a sentiment we can all relate to—that home is a feeling,” said John Reed, Co-Founder and CEO of Arhaus. “It’s a celebration of the rhythms of everyday life and the joy of building a home that is filled with beauty, comfort, and a story that is wholly yours.”

The cover of the 2025 style issue, ‘Home & Style,’ reflects this ethos, showcasing how Arhaus encourages clients to curate layered, personal spaces that feel collected over time. Modern silhouettes mix with traditional forms; stone and wood balance against custom upholstery; and antiques sit comfortably alongside new additions. The result is a look that feels timeless, dimensional, and distinctly Arhaus.

“Our assortment is about individuality, not uniformity. Whether exploring our unmatched custom upholstery options, or selecting a piece to complement a family heirloom, our pieces are designed to work together in ways that honor your style. This season’s introductions capture what makes Arhaus truly special: an enduring invitation to design a home that feels like you.”

The Fall 2025 Collection debuts new designs and expands signature favorites across dining, living, and more, with features throughout of graceful silhouettes, richly grained woods, and designs that bring people together. Soft, rounded forms lend a sense of ease and movement, as seen in the new Milana Collection—its crescent-shaped silhouette, inspired by midcentury Italian design, is upholstered in the dimensional richness of velvet. The iconic Finnley Collection, known for its reeded-oak detailing, now extends into seating for the first time, pairing signature wood craftsmanship with a welcoming profile. The Blaire Round Chandelier continues the theme, its molten glass panels overlapping in layers that diffuse light with architectural elegance.

Rich, deep wood tones take center stage in the Fall 2025 Collection. The chocolate hue of American walnut brings warmth and refinement to designs like the James Bookcase and Frances Sideboard, showcasing the wood’s timeless appeal and versatility. In contrast, the Morley Bedroom Collection highlights the intricate, swirling grain patterns of walnut burl—a rare and highly prized cut that turns each piece into a one-of-a-kind work of art.

As the season turns toward gathering, the collection brings forward designs that celebrate connection around the table. The Caden Dining Table pairs vibrant black Marquina marble with dimensional walnut veneers, while the Jolson Extension Dining Table combines solid oak with graceful proportions and adaptability for hosting. With seating like the woven Myers Dining Chair, these pieces create inviting spaces where meals and conversations flow long after the plates are cleared.

Arhaus has long been proud of its artisan-crafted pieces and the lasting relationships it has built with the people behind them. Within the pages of the ‘Home & Style’ catalog, the brand shares the story of its fifth-generation partners in Northern Romania—artisans who have been creating heirloom-quality furniture for more than a century. Led by father-and-son team Viorel and Voicu, their family-run workshop shapes American walnut into the forms that define the beloved Mihaela and Cortina collections. Cortina, known for its soft lines inspired by the movement of curtains in a breeze, debuts new expansions this season, including a round dining table and a sideboard—continuing a legacy of artistry that, as Viorel says, begins with the belief that “Every log tells a story.”

This fall Arhaus also celebrates its entry into the bath category with the recent debut of Arhaus Bath, one of Arhaus’ most comprehensive category expansions to date—extending its signature ethos and aesthetic into a new room of the home. The Arhaus Bath collection—which includes a full suite of vanities, hardware, bath linens, and more—features sculptural forms, rich materials, and refined finishes, reinforcing a focus on quality and detail at every touchpoint. Beloved styles like the reeded Finnley and gracefully curved Calista collections now extend to the bath, creating a harmonious flow throughout the home.

Additional highlights within the Fall 2025 collection include:

• 
  Sumner Collection
  : Handcrafted in North Carolina with materials from around the world, Sumner’s uniquely layered upholstery design pairs clean lines with performance fabric for durable, enduring style—offering versatile seating options to suit a variety of spaces.
• 
  Norwalk Collection
  : Built for everyday comfort, Norwalk is handcrafted in North Carolina with soft, supportive materials from around the world and a timeless silhouette designed for both style and relaxation.
• 
  Harrow Collection
  : A study in balance, the Harrow Collection blends rounded edges with rich materials for a sense of understated elegance offered in bedroom, dining, console, coffee table, and cabinet styles.
• 
  Henton Collection
  : Sleek and contemporary, the new Henton Collection offers three high-gloss silhouettes—including a nightstand, five-drawer dresser, six-drawer dresser, and media console.
• 
  Giselle Collection
  : A new antique-inspired bedroom suite, including a Six-Drawer Dresser and Nightstand, crafted from reeded mahogany in a rich Canaletto finish with Black Marquina marble veneer tops.
• 
  Linley Glass Cabinet
  : Defined by arched, tempered-glass doors and topped with Carrara stone, the Linley Glass Cabinet offers a sophisticated balance of display and storage.
• 
  Lunaria Chandelier
  : Handcrafted in Italy from ceramic and iron with a matte finish, Lunaria’s soft, refined glow and delicately shaped petals echo the organic beauty of its namesake plant.

To discover how pieces from the Fall 2025 Collection can be brought to life in home projects of any size, Arhaus’ complimentary Interior Design services are available in-showroom, virtually, or at home. Designers collaborate on every detail—from space planning and color palettes to material selections—creating environments tailored to individual style and needs. These services also make it possible to fully explore Arhaus’ upholstery customization, with hundreds of fabrics and leathers available across seating collections, offering endless opportunities for personalization. To connect with an Arhaus Interior Designer, visit Arhaus.com/DesignServices.

New arrivals from the Fall 2025 Collection are now available at Arhaus.com and in Arhaus showrooms nationwide. For more inspiration and to experience the full assortment, visit Arhaus.com or your nearest showroom at Arhaus.com/Stores.

About Arhaus

Founded in 1986, Arhaus is a growing lifestyle brand and omni-channel retailer of premium home furnishings. Through a differentiated proprietary model that directly designs and sources products from leading manufacturers and artisans around the world, Arhaus offers an exclusive assortment of heirloom quality products that are sustainably sourced, lovingly made, and built to last. With more than 100 showroom and design studio locations across the United States, a team of interior designers providing complimentary in-home design services, and robust online and eCommerce capabilities, Arhaus is known for innovative design, responsible sourcing, and client-first service. For more information, please visit www.arhaus.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9c51de39-9a8f-4d50-b4a0-74434de108da

Arhaus Public Relations Department
[email protected] 

Hong Kong, Aug. 27, 2025 (GLOBE NEWSWIRE) — Skyline Builders Group Holding Limited (NASDAQ: SKBL) (the “Company”), a civil engineering services provider in Hong Kong, today announced that it has entered into a definitive securities purchase agreement dated August 27, 2025 with accredited investors for the issuance and sale (the “Offering”) of up to 24,349,315 Class A Ordinary Shares, par value $0.00001 per share (each, a “Class A Ordinary Share”) and/or prefunded warrants to purchase Class A Ordinary Shares (the “Prefunded Warrants”) in lieu of Class A Ordinary Shares, at a price of $0.73 per share, together with the Company’s Class A Ordinary Share Purchase Warrant As to purchase up to 24,349,315 Class A Ordinary Shares (the “A Warrants”) and the Company’s Class A Ordinary Share Purchase Warrant Bs to purchase up to 24,349,315 Class A Ordinary Shares (the “B Warrants”) in a brokered private placement on a best-efforts basis, for a combined aggregate gross proceeds of approximately $17,775,000, before deducting fees and offering expenses.

Each Pre-funded Warrant will entitle the holder to acquire one Ordinary Share at an exercise price of $0.0001 per share; each A Warrant will be immediately exercisable and entitle the holder to acquire one Class A Ordinary Share at an exercise price of $0.60 per share, for a period of five years following the closing of the Offering; and each B Warrant will be immediately exercisable and entitle the holder to acquire one Class A Ordinary Share at an exercise price of $0.65 per share, for a period of five years following the closing of the Offering. The private placement is expected to close on August 27, 2025, subject to customary closing conditions.

The Company shall use the net proceeds from the sale of the securities hereunder as follows: (a) the Company shall use approximately $7,000,000 from the proceeds to retire the 18,500,000 Class A Ordinary Shares of the Company owned by Supreme Development (BVI) Holdings Limited, a company which is beneficially owned by Ngo Chiu Lam, the Company’s Chief Executive Officer; and (b) the Company shall use the remaining proceeds for general working capital and other general corporate purposes. The Company intends to use the proceeds from the offering for working capital and general corporate purposes.

Dominari Securities LLC, Revere Securities LLC and Pacific Century Securities are acting as co- placement agents for the Offering.

The securities offered and sold by the Company in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the “SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the Class A Ordinary Shares, and the shares underlying the Pre-funded Warrants, the A Warrants and the B Warrants to be issued in the private placement. Any resale of the Company’s shares under such resale registration statement will be made only by means of a prospectus.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities will not be registered under the Securities Act or any state securities laws when issued at the closing of the private placement, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state laws.

About Skyline Builders Group Holding Limited

Skyline Builders Group Holding Limited (NASDAQ: SKBL) operates as an Approved Public Works Contractor undertaking roads and drainage to its customers in Hong Kong. Its construction activities mainly include public civil engineering works, such as road and drainage works, in Hong Kong. It mostly undertakes civil engineering works in the role of subcontractor, while it is also fully qualified to undertake such works in the capacity of main contractor. The Company’s public sector projects mainly involve infrastructure developments while private sector projects mainly involved residential and commercial developments.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. These forward-looking statements include statements regarding the proposed Share Consolidation, the Company’s ability to grow its business, and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.

For more information, please contact:

Skyline Builders Group Holding Limited

Investor Relations Department
Email: [email protected]

Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8)

Median OS of 2

^nd

Line efficacy evaluable population of 12 months (n=9)

Median OS of Intent to Treat population (1L-7L) of 9 months (n=22)

OS demonstrated by Annamycin in the MB-106 trial is significantly above industry expectations for relapsed AML (4-6 months)

Clinical study report anticipated in Q1 2026

Company continues to execute Part A of the pivotal MIRACLE Phase 3 trial

HOUSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced the completion of its Phase 1B/2 (MB-106) clinical trial evaluating Annamycin in combination with Cytarabine (also known as “Ara-C” and for which the combination of Annamycin and Ara-C is referred to as AnnAraC) for the treatment of subjects with acute myeloid leukemia (AML). Database lock for the trial is expected by the end of September, with the final clinical study report (CSR) projected to be published in early Q1 2026.

In total, 22 subjects were enrolled in the trial, with all subjects (1L-7L) who received AnnAraC per protocol having completed their efficacy evaluations (n=20). The updated overall survival (OS) data reveal the following:

• Median OS for Complete Remissions (CR): 15 months (n=8) with 4 subjects alive at study close
• Median OS for the intent to treat (ITT) Population (1L-7L): 9 months (n=22; 13 subjects experienced an event, 9 subjects censored)
• Median OS for 2L Efficacy Evaluable Population: 12 months (n=9)

“Industry publications¹ note that the typical OS for relapsed AML patients is roughly 4-6 months, these results highlight a remarkable improvement, exceeding expectations by 30% or more,” said Walter Klemp, Chairman and CEO of Moleculin Biotech.

As previously reported, 8 subjects in the ITT population of 22 (36%) achieved a complete remission (CR) following treatment with AnnAraC. Among the subjects treated in the second line (2L) setting (n=10), the CR rate (the same primary efficacy endpoint as in the ongoing Phase 2B/3 pivotal MIRACLE trial), was 50%. Median durability for the 8 subjects achieving a CR was 10 months and continuing at the end of the study. CR durability ranged from 2 months to 22 months. CRs were achieved in subjects with a variety of prior treatments, including traditional 7+3 and venetoclax regimens.

“We are glad to finally be in a position to close out our last Phase 2 AML trial, MB-106 by having completed follow-up on all subjects – some with durable CRs continuing – with database lock expected by the end of next month. While still technically preliminary, we are extremely pleased with the results of the MB-106 trial and look forward to the final CSR. These 2L data formed the basis for the design of the Phase 2B/3 pivotal MIRACLE trial with which we aim to gain eventual approval of Annamycin to serve the unmet need in 2L AML,” added Walter Klemp, Chairman and CEO of Moleculin. “We continue to see meaningful, positive trends across all data points, particularly in overall survival and durability. Of note, an 80+ yr old subject who achieved a CR with one cycle of Annamycin and then received two maintenance cycles of Annamycin finally relapsed after 600+ days. He then received a fourth round of Annamycin under compassionate use and is now back in remission. These data are very exciting and continue to give us hope that Annamycin has the potential to address the significant unmet need for safe and effective therapies for R/R AML. We also need to reemphasize that we have not seen any cardiotoxicity in any of the subjects to date, a key aspect of Annamycin.”

“We can now also report that 50% of subjects achieving CR moved on to a curative bone marrow transplant, which is the most sought-after goal of any induction therapy in AML,” Mr. Klemp continued. “The results we have seen in 2L patients are better than any drug ever approved for second line AML and more than double the average for the last five drugs approved for 2L use.”

“Looking ahead, we are focused on driving Part A of our Phase 3 MIRACLE trial forward and remain on track recruit the first 45 enrolled patients before the end of this year on which safety and efficacy will be unblinded. The final data from MB-106, coupled with the expected data from the MIRACLE trial will be invaluable as we continue to unlock the full potential of Annamycin for the treatment of AML,” concluded Mr. Klemp.

The median age of subjects in MB-106 is 68 years. A total of 18 subjects had relapsed/refractory AML and 4 subjects were first line treatment. Two subjects discontinued early due to allergic reactions. All subjects who completed treatment had undergone post therapy disease response assessments (bone marrow assessment and/or peripheral blood evaluation) (Day 15 or later). No clinically significant signs of cardiotoxicity were noted during or after treatment in any of the subjects enrolled. The combination was well tolerated with myelosuppression and infections being the main adverse events (AEs). All data from MB-106 is preliminary and subject to change.

Annamycin, also known by its non-proprietary name of naxtarubicin, currently has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory acute myeloid leukemia, in addition to Orphan Drug Designation for the treatment of soft tissue sarcoma. Furthermore, Annamycin has Orphan Drug Designation for the treatment of relapsed or refractory acute myeloid leukemia from the EMA.

The Company is currently evaluating Annamycin in combination with Cytarabine (also known as “Ara-C” and for which the combination of Annamycin and Ara-C is referred to as “AnnAraC”) in a Phase 3 pivotal trial for the treatment of AML patients who are refractory to or relapsed after induction therapy (R/R AML). This global Phase 3 “MIRACLE” trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation) includes sites in the US, Europe and the Middle East. For more information about the MIRACLE trial, visit clinicaltrials.gov and reference identifier NCT06788756. Additionally, the clinical trial in the EU is on euclinicaltrials.eu and the reference identifier there is 2024-518359-47-00.

1 – Bruno C. Medeiros, Is there a standard of care for relapsed AML?, Best Practice & Research Clinical, Haematology, Volume 31, Issue 4, 2018, Pages 384-386, ISSN 1521-6926; Roboz GJ, Sanz G, et al. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood Adv. 2024 Apr 23;8(8):2020-2029. doi: 10.1182/bloodadvances.2023012062. PMID: 38231126; PMCID: PMC11103175.; Faderl S, Wetzler M, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012 Jul 10;30(20):2492-9. doi: 10.1200/JCO.2011.37.9743. Epub 2012 May 14. PMID: 22585697; PMCID: PMC4874149.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the MB-106 database lock for the trial and the publication of the final CSR, the timing of the release of the initial data on the first 45 subjects in the MIRACLE trial, and the Company’s ability to reconcile the US and EU MIRACLE protocols with the FDA and EMA, respectively. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected] 

Led by Prof. Dr. Marianne Brodmann, PI of clinical studies for the Lumee™ Oxygen CE Mark, collaboration includes practice adoption and platform integration in cases and clinical study programs

BERKELEY, Calif, Aug. 27, 2025 (GLOBE NEWSWIRE) — Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces a commercial and clinical collaboration with Prof. Dr. Marianne Brodmann at the Medical University of Graz, Austria. Under the collaboration, Prof. Brodmann will adopt the Lumee oxygen platform technology in her practice of approximately 1,500 annual vascular procedures.  In addition, as principal investigator (PI) of clinical studies that supported Lumee oxygen in its CE marking, Prof. Brodmann intends to integrate Profusa’s platform technology in cases and clinical study programs.

“Real-time oxygen perfusion data for patients suffering from critical limb ischemia is critical for the proper monitoring of patients during surgery and as they recover,” said Prof. Brodmann. “As an experienced user of Profusa’s technology through leading portions of Profusa’s clinical studies, I am convinced that the Lumee Oxygen platform meets an important clinical need.  I am excited to adopt the Lumee Oxygen system to improve patient outcomes and continue to explore ways for clinical communities to use Lumee Oxygen to improve patient care.”

Prof. Dr. Marianne Brodmann is a board member of the European Union of Medical Specialists and a fellow at the European Society of Cardiology (ESC). She served as the president of the Austrian Society of Angiology, a national delegate for the International Union of Angiology, and had been a member of various groups such as ESC Working Group on Aorta & Peripheral Vascular Diseases and Nucleus ÖGIA. She has been involved with more than 50 international trials, researching, among many topics, anticoagulation, thrombolysis, restenosis, and new technologies in the endovascular field.  Prof. Brodmann has over 100 publications listed on PubMed Central.

“Our continued collaboration with Prof. Brodmann and the Medical University of Graz, Austria provides additional validation for our Lumee technology platform, and we are proud to add the practice to our commercial network,” said Ben Hwang, Ph.D., Profusa’s Chairman and CEO.  “We also look forward to the integration of our platform technology into Prof. Brodmann’s cases and clinical studies in a drive for additional indications for use of our proprietary technology, expanding our market reach.”

About Profusa

Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.

“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.

For more information, visit https://profusa.com.

Special Note Regarding Forward-Looking Statements

Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa or the combined company. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including risks regarding the highly volatile nature of the price of Bitcoin and other cryptocurrencies, as well as the risk that the Company’s stock price may be highly correlated to the price of the digital assets that it holds. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and described in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.

Contacts

Investor and Media Contacts

email:  [email protected]
phone:  1 (212) 655-0924

LIVERMORE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) — Advent Technologies Holdings, Inc. (NASDAQ: ADN), an innovation-driven leader in fuel cells and hydrogen technologies, is pleased to announce that it has engaged Fata Advisory, LLC to support the Company’s strategic outreach and business development with key U.S. government, commercial, and potential foreign customers in deploying Advent’s power generation products for the aerospace, defense, and commercial markets.

The firm’s founder and principal, Daniel Fata, has more than 30 years of experience working in the Department of Defense, Congress, as well as the U.S. and international aerospace and defense industries including Lockheed Martin. He is an expert on strategy and issues regarding U.S. national security, government relations, and defense contract procurement.

Gary Herman, Advent’s Chief Executive Officer stated: “we are pleased to have someone with Dan’s depth of experience and strong personal connections in the defense industry to assist us in broadening our outreach with the Department of Defense and other federal agencies as well as our continued expansion into the aerospace and defense industries.”

Daniel Fata added “I am excited to be helping Advent expand their customer base and to get their cutting-edge power generation technologies into the hands of those who need them today. Given the operational energy needs of the dismounted soldier, the firefighter, the border guard as well as those operating at great distances for sustained periods where independent power generation is essential, Advent’s family of products provide precisely the solutions needed to operate during long durations with a minimal logistical footprint.”

About Advent Technologies Holdings, Inc.

Advent Technologies Holdings, Inc. is a U.S. corporation that develops, manufactures, and assembles complete fuel cell systems as well as supplying customers with critical components for fuel cells in the renewable energy sector.  Advent is headquartered in Livermore, California, with offices in Athens, Patras and Kozani, Greece.  With approximately 150 patents issued, pending, and/or licensed for fuel cell technology, Advent holds the IP for next-generation HT-PEM that enables various fuels to function at high temperatures and under extreme conditions – offering a flexible fuel option for the automotive, aviation, defense, oil and gas, marine, and power generation sectors. For more information, visit www.advent.energy.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements.  These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning.  Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.  Applicable risks and uncertainties include, among others, the Company’s ability to maintain the listing of the Company’s common stock on Nasdaq; future financial performance; public securities’ potential liquidity and trading; impact from the outcome of any known and unknown litigation; ability to forecast and maintain an adequate rate of revenue growth and appropriately plan its expenses; expectations regarding future expenditures; future mix of revenue and effect on gross margins; attraction and retention of qualified directors, officers, employees and key personnel; ability to compete effectively in a competitive industry; ability to protect and enhance Advent’s corporate reputation and brand; expectations concerning its relationships and actions with technology partners and other third parties; impact from future regulatory, judicial and legislative changes to the industry; ability to locate and acquire complementary technologies or services and integrate those into the Company’s business; future arrangements with, or investments in, other entities or associations; and intense competition and competitive pressure from other companies worldwide in the industries in which the Company will operate; and the risks identified under the heading “Risk Factors” in Advent’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on June 6, 2025, as well as the other information filed with the SEC. Investors are cautioned not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read Advent’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties.  The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements. Advent’s business is subject to substantial risks and uncertainties, including those referenced above.  Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contact:
Advent Technologies Holdings, Inc.
[email protected]